Cara Therapeutics
Cara Therapeutics develops therapies for chronic pruritus, with a focus on advanced chronic kidney disease and hemodialysis, and has launched the FDA-approved KORSUVA® Injection for pruritus in hemodialysis patients.
Company Overview
Cara Therapeutics is dedicated to developing therapies for chronic pruritus. The company, headquartered at 400 Atlantic Street, Suite 500, Stamford, CT 06901, focuses on leveraging its leading product, difelikefalin, to potentially treat various pruritus-associated diseases. Cara Therapeutics aims to transform pruritus treatment to enhance the quality of life for millions.
Flagship Product: KORSUVA® Injection
KORSUVA® Injection is the first and only FDA-approved treatment for moderate to severe pruritus associated with chronic kidney disease in adults undergoing hemodialysis. This product is also approved in the EU, UK, Iceland, Liechtenstein, Norway, and Switzerland under the tradename Kapruvia™. Cara Therapeutics holds multiple U.S. patents for KORSUVA®, including Patent Nos. 7,402,564, 7,713,937, and 8,217,007.
Research and Development
Cara Therapeutics is conducting the KOURAGE Study to investigate the use of difelikefalin for pruritus in Notalgia Paresthetica, a neuropathic itch typically affecting the upper back. The company is committed to extending its research on pruritus treatment in advanced chronic kidney disease and hemodialysis.
Strategic Collaborations
Cara Therapeutics collaborates with Vifor Fresenius Medical Care Renal Pharma (VFMCRP) for the commercialization of difelikefalin outside the U.S. for specific indications. This strategic partnership aims to expand the reach of difelikefalin to a broader patient population worldwide.
Commitment to ESG Principles
Cara Therapeutics is committed to adhering to environmental, social, and governance (ESG) principles. The company's strategy includes fostering a hybrid work policy that combines in-office collaboration with remote work flexibility, ensuring both employee satisfaction and operational efficiency.